Literature DB >> 27891454

Efficacy and Safety of Intralesional Xantinol Nicotinate in the Treatment of Various Stages of Oral Submucous Fibrosis.

Udita Singh1.   

Abstract

INTRODUCTION: Oral Submucous Fibrosis (OSMF) is one of the most prevalent potentially malignant disorders seen in South east population since ages. Despite the extensive amount of research held in this field, its treatment still remains a challenge. In this study, we present our experience in successfully managing OSMF with intralesional injections of a peripheral vasodilator namely xantinol nicotinate. AIM: To determine the efficacy and safety of intralesional xantinol nicotinate in the treatment of various stages of OSMF.
MATERIALS AND METHODS: This parallel, prospective, clinical study included 60 patients clinically diagnosed with oral submucous fibrosis divided into two groups. Group I patients were subjected to intralesional xantinol nicotinate injections bi-weekly for a period of four months while Group II patients were given intralesional saline injections biweekly for four months. All the patients were instructed to perform home mouth opening physiotherapy exercises. At each visit, parameters like increase in interincisal distance, cheek flexibility, tongue protrusion and relief from burning sensation and any side effects were measured and recorded. The drop out figure was zero.
RESULTS: At the end of four months, in Group I, there was an increase in mean values of interincisal distance, cheek flexibility and tongue protrusion (p<0.001). For burning sensation a significant decrease in mean value was observed (p<0.001). Whereas, in Group 2 the difference between pre-treatment and post-treatment values was not statistically significant (p>0.001). On comparing the results of Group 1 and Group 2, statistically significant difference was observed (p<0.001).
CONCLUSION: Xantinol nicotinate, a peripheral vasodilator, when injected intralesionally in OSMF patients not only provides relief from burning sensation but also results in increased mouth opening, tongue protrusion and cheek flexibility.

Entities:  

Keywords:  Adjunct; Antioxidant; Peripheral vasodilator; Potentially malignant disorder; Supportive therapy

Year:  2016        PMID: 27891454      PMCID: PMC5121800          DOI: 10.7860/JCDR/2016/20138.8639

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  7 in total

1.  Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis.

Authors:  R Rajendran; Vidya Rani; Saleem Shaikh
Journal:  Indian J Dent Res       Date:  2006 Oct-Dec

2.  Xanthinol nicotinate in peripheral vascular disease.

Authors:  E Davis; H Rozov
Journal:  Practitioner       Date:  1975-12

3.  Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

Authors:  Kang Cheng; Tsuei-Ju Wu; Kenneth K Wu; Claudio Sturino; Kathleen Metters; Keith Gottesdiener; Samuel D Wright; Zhaoyin Wang; Gary O'Neill; Eseng Lai; M Gerard Waters
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

Review 4.  Effect of tumor cells and tumor microenvironment on NK-cell function.

Authors:  Massimo Vitale; Claudia Cantoni; Gabriella Pietra; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Eur J Immunol       Date:  2014-06       Impact factor: 5.532

5.  [Effect of pentoxyfylline and xanthinol nicotinate on the overall blood pressure and tonus of cerebral and peripheral vessels].

Authors:  M D Gaevyĭ; T V Sankina; G V Nagornaia
Journal:  Farmakol Toksikol       Date:  1984 Jan-Feb

6.  Oral submucous fibrosis in India: a new epidemic?

Authors:  P C Gupta; P N Sinor; R B Bhonsle; V S Pawar; H C Mehta
Journal:  Natl Med J India       Date:  1998 May-Jun       Impact factor: 0.537

7.  Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms.

Authors:  K Bieroń; J Swies; E Kostka-Trabka; R J Gryglewski
Journal:  J Physiol Pharmacol       Date:  1998-06       Impact factor: 3.011

  7 in total
  1 in total

1.  Medicinal management of oral submucous fibrosis in the past decade- A systematic review.

Authors:  Chandramani B More; Deepa Jatti Patil; Naman R Rao
Journal:  J Oral Biol Craniofac Res       Date:  2020-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.